Researchers presented three studies on Zimmer Biomet's Mobi-C Cervical Disc at the 2017 French Spine Society Congress, held June 1 to June 3 in Lille.
Here are five highlights:
1. Used to treat cervical total disc replacement, Mobi-C is intended to keep range of motion and flexibility intact after surgery.
2. The three studies illustrate Mobi-C's short- and long-term safety, efficacy and patient satisfaction.
3. One study, "Prevalence, Progression, and Clinical Implications of Heterotopic Ossification after Cervical Disc Arthroplasty at 7 years," found no patients underwent subsequent CTDR due to heterotopic ossification after treatment with the Mobi-C.
4. Another study, "Clinical Results of Cervical Total Disc Replacement with a Self-Adjusting Mobile Core Prosthesis after 10-Year Follow-Up," revealed TDR with a device like Mobi-C was effective and safe.
5. The third study, "Reemergence of Symptoms after Successful Treatment with Cervical Disc Arthroplasty or Anterior Cervical Discectomy and Fusion between 2 to 5 years follow-up," found cervical TDA with Mobi-C treatment was more effective than anterior cervical discectomy and fusion.